128 related articles for article (PubMed ID: 3623240)
1. The use of amsacrine plus intermediate-dose cytosine arabinoside in relapsed and refractory acute nonlymphocytic leukemia.
Dekker AW; Punt K; Verdonck LF
Haematol Blood Transfus; 1987; 30():333-5. PubMed ID: 3623240
[No Abstract] [Full Text] [Related]
2. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED
J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446
[TBL] [Abstract][Full Text] [Related]
3. Intermediate-dose cytosine arabinoside and amsacrine. An effective regimen with low toxicity in refractory acute nonlymphocytic leukemia.
Dekker AW; Nieuwenhuis HK; Verdonck LF
Cancer; 1990 May; 65(9):1891-4. PubMed ID: 2372760
[TBL] [Abstract][Full Text] [Related]
4. Combined chemotherapy with m-amsacrine in high-risk patients with acute non-lymphocytic leukemia.
Maschmeyer G; Hiddemann W; Kreutzmann H; Wendt F
Onkologie; 1987 Feb; 10(1):18-21. PubMed ID: 3295621
[TBL] [Abstract][Full Text] [Related]
5. Prolonged survival after high-dose cytosine arabinoside and amsacrine induction in patients with previously untreated de novo acute nonlymphocytic leukemia.
Hines JD; Mazza JJ; Oken MM; Adelstein DJ; Keller A; Bennett JM; O'Connell MJ
Semin Oncol; 1987 Jun; 14(2 Suppl 1):37-9. PubMed ID: 3296207
[No Abstract] [Full Text] [Related]
6. High-dose cytosine arabinoside, daunomycin and 6-thioguanine in relapsed or refractory acute nonlymphocytic leukemia.
Garewal H; Durie BG; Greenberg B
Oncology; 1987; 44(6):333-5. PubMed ID: 3684173
[TBL] [Abstract][Full Text] [Related]
7. High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia.
Hines JD; Oken MM; Mazza JJ; Keller AM; Streeter RR; Glick JH
J Clin Oncol; 1984 Jun; 2(6):545-9. PubMed ID: 6233399
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
[TBL] [Abstract][Full Text] [Related]
9. High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase I Pilot Study for the Eastern Cooperative Oncology Group.
Hines JD; Mazza JJ; Oken MM; Bennett JM; Adelstein DJ; Keller A; O'Connell MJ
Semin Oncol; 1985 Jun; 12(2 Suppl 3):117-9. PubMed ID: 3839318
[No Abstract] [Full Text] [Related]
10. Sequential pilot studies of intensive postremission chemotherapy for acute nonlymphocytic leukemia.
Petti MC; Avvisati G; Tafuri A; Meloni G; Amadori S; Mandelli F
Ann N Y Acad Sci; 1987; 511():436-41. PubMed ID: 3326472
[No Abstract] [Full Text] [Related]
11. Results of induction and consolidation treatment with intermediate and high-dose cytosine arabinoside and m-Amsa of patients with poor-risk acute myelogenous leukaemia.
Peters WG; Willemze R; Colly LP
Eur J Haematol; 1988 Mar; 40(3):198-204. PubMed ID: 3162718
[TBL] [Abstract][Full Text] [Related]
12. Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia.
Cassileth PA; Begg CB; Silber R; Spiers A; Burkart PT; Scharfman W; Knospe WH; Bennett JM; Mazza JJ; Oken MM
Cancer Treat Rep; 1987 Feb; 71(2):137-40. PubMed ID: 3802110
[TBL] [Abstract][Full Text] [Related]
13. High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomized study.
Martiat P; Ghilain JM; Ferrant A; Doyen C; Delannoy A; Chatelain C; Bosly A; Michaux JL; Sokal G
Eur J Haematol; 1990 Sep; 45(3):164-7. PubMed ID: 2226729
[TBL] [Abstract][Full Text] [Related]
14. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
Jehn U; Heinemann V
Haematol Blood Transfus; 1990; 33():333-8. PubMed ID: 1691134
[TBL] [Abstract][Full Text] [Related]
15. Combination amsacrine and high-dose cytosine arabinoside in acute leukemia.
Arlin ZA
J Clin Oncol; 1985 Jan; 3(1):128. PubMed ID: 3838101
[No Abstract] [Full Text] [Related]
16. Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leukemia with cytosine arabinoside, daunorubicin, and m-AMSA.
Roubenoff R; Jones RJ; Karp JE; Stevens MB
Arthritis Rheum; 1987 Oct; 30(10):1187-90. PubMed ID: 3479115
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acute leukemia with amsacrine and high-dose cytarabine.
Arlin ZA; Gaddipati J; Ahmed T; Mittelman A; Friedland M; Rieber E
Cancer Treat Rep; 1985 Sep; 69(9):1001-2. PubMed ID: 3839713
[TBL] [Abstract][Full Text] [Related]
18. High-dose cytosine arabinoside with amsacrine for treatment of acute lymphoblastic leukemia.
Arlin ZA
J Clin Oncol; 1986 Dec; 4(12):1868. PubMed ID: 3465878
[No Abstract] [Full Text] [Related]
19. [Intermediate-dose cytosine arabinoside therapy in refractory acute leukemia].
Ohshima A; Yoshida K; Miyazaki S; Fukushima Y; Miura AB; Endo K; Ando H; Sasaki H; Saito S; Sato I
Gan To Kagaku Ryoho; 1989 Jan; 16(1):139-42. PubMed ID: 2643393
[No Abstract] [Full Text] [Related]
20. Chemotherapy for relapsed and resistant acute nonlymphoblastic leukemia. Effect of ATA, an amsacrine-containing regime.
Liang R; Chan TK; Todd D
Cancer Chemother Pharmacol; 1988; 21(1):68-70. PubMed ID: 3342467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
